Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5,630 JPY | 0.00% | -2.76% | +3.11% |
30/04 | Genky Drugstores Co., Ltd. Reports Sales Results for the Month and Third Quarter Ended April 2024 | CI |
25/04 | Genky Drugstores Co., Ltd. Provides Dividend Guidance for the Fiscal Year 2023 | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.61 for the 2024 fiscal year.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Sales forecast by analysts have been recently revised upwards.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For the past twelve months, EPS forecast has been revised upwards.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company does not generate enough profits, which is an alarming weak point.
- The company is not the most generous with respect to shareholders' compensation.
Ratings chart - Surperformance
Sector: Drug Retailers
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+3.11% | 559M | - | ||
-31.79% | 15.36B | B- | ||
-21.99% | 12.45B | B | ||
-22.64% | 6.75B | B | ||
+9.74% | 6.14B | C | ||
-10.91% | 6.07B | C+ | ||
+0.29% | 4.78B | D- | ||
+59.24% | 4.53B | - | C | |
-9.00% | 3.81B | B | ||
-12.53% | 3.43B | C- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 9267 Stock
- Ratings Genky DrugStores Co., Ltd.